NR3C2 and hydrops fetalis: Further studies are needed in animal models, to clarify the mechanism by which EC‐MR contributes to HF and also in patients, to determine whether MR antagonists may be beneficial in subsets of patients with HFpEF for which there are no other efficacious therapies.